Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with advanced malignant solid tumors
ECOG Performance Status of ≤ 2
Patients must have the following laboratory values:
Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L, Hemoglobin (Hgb) ≥ 8.5 g/dl, Platelets (plt) ≥ 100 x 109/L
Potassium, Calcium, Magnesium, Phosphorus within normal limits or correctable with supplements
AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN)
Serum bilirubin ≤ 1.5 x ULN, Serum albumin > 2.5g/dl, Serum creatinine≤ 1.5 x ULN or 24-hour clearance ≥ 50 ml/min
Able to sign informed consent and to comply with the protocol
Patients with brain metastasis.
Prior treatment with any HSP90 or HDAC inhibitor compound.
Treatment with therapeutic doses of coumarin anticoagulants.
Pregnant and lactating women.
Severe and/or uncontrolled acute or chronic liver disease
Severe and/or uncontrolled acute or chronic renal disease
Chronically significant heart disease
History (or family history) of long QT syndrome. QTc ≥ 450 msec on screening ECG, ischemic heart disease, heart fail, ECG abnormalities, atrial fibrillation, atrial flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de Pointes.
Patients who are currently receiving treatment with any medication which has a relative risk or prolonging the QTcF interval or inducing Torsades de Pointes
Patients with known disorders due to a deficiency in bilirubin glucuronidation (e.g Gilbert's syndrome).
Other protocol-defined inclusion/exclusion criteria may apply